Our end-to-end CDMO services are fully integrated and tailored to your needs: from formulation to fill & finish, small-scale or larger quantities.
With cutting edge technology and GMP approval from regulatory agencies:
FDA | EMA | TGA (Australia) | PDMA (Japan) | ANMAT (Argentina) | COFEPRIS (Mexico) Canada | ANVISA (Brazil) (among others)
We have a proven track record in delivery of high-value, high-profile biological projects, from innovators to biosimilars.
Monoclonal
Chimeric
Bispecific
Virus vector-based vaccines
Adenovirus vaccines
Vaccinia vector-based
Fc Fusions
Multispecific proteins
Our portfolio of biopharmaceuticals targets areas of oncology, hematology, osteoporosis and pediatrics.
End-to-end expertise and capabilities across development of the cell line, formulation, and manufacturing processes for DS and DP, along with robust design and execution of clinical trials.
Strong internal IP portfolio extending beyond research and development to encompass production IP, which ensures our competitive edge in the marketplace.
Outstanding regulatory capabilities with strong scientific review processes and leadership in submissions. Established track records with regulatory authorities worldwide.